Takeda Pharmaceutical (TAK) Equity Income (2018 - 2020)

Takeda Pharmaceutical (TAK) posted quarterly Equity Income of $5.3 billion for Q3 2020, up 189.53% quarter-over-quarter from $1.8 billion in Q1 2020.

Takeda Pharmaceutical (TAK) Equity Income (2018 - 2020) Analysis & Trends

Takeda Pharmaceutical's Equity Income history runs 3 years deep, the most recent figure standing at $5.3 billion for Q3 2020.

In Q3 2020, Equity Income changed N/A year-over-year to $5.3 billion; the TTM figure through Sep 2020 stood at $6.5 billion (changed N/A YoY), while the FY2020 annual figure was $1.8 billion, up 560.91% from the prior year.
Equity Income for Q3 2020 stood at $5.3 billion, up from $1.8 billion in the prior quarter.
The five-year high for Equity Income was $5.3 billion in Q3 2020, with the low at -$604.7 million in Q1 2018.
The 3-year median for Equity Income is $911.1 million (2019), against an average of $1.6 billion.
The sharpest annual moves came in 2019 and 2020: Equity Income surged 100.0% in 2019, then jumped 205331553394.47% in 2020.
Takeda Pharmaceutical's Equity Income stood at -$604.7 million in 2018, then jumped by 100.0% to $0.89 in 2019, then soared by 594491215228.45% to $5.3 billion in 2020.
Business Quant data shows TAK's Equity Income at $5.3 billion in Q3 2020, $1.8 billion in Q1 2020, and $0.89 in Q1 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Haleon	43.81 Bn	42.84 Bn	-	-
2	Teva Pharmaceutical Industries	43.29 Bn	39.63 Bn	2.15 Bn	-500,000.00
3	Zoetis	31.59 Bn	29.91 Bn	1.05 Bn	-
4	Takeda Pharmaceutical	28.67 Bn	22.88 Bn	5.10 Bn	3.38 Mn
5	United Therapeutics	22.24 Bn	19.58 Bn	683.80 Mn	-
6	Viatris	18.79 Bn	17.91 Bn	1.46 Bn	-
7	Neurocrine Biosciences	15.71 Bn	15.32 Bn	935.80 Mn	-
8	Elanco Animal Health	12.09 Bn	11.56 Bn	798.00 Mn	-
9	Dr Reddys Laboratories	10.11 Bn	9.95 Bn	-	-
10	Alkermes	8.19 Bn	7.53 Bn	397.90 Mn	-

Download Data